Researchers Discover Alzheimer's Disease Disrupts the 3D Architecture of DNA in Brain Cells

Alzheimer's disease physically distorts the 3D architecture of DNA inside brain cells, causing active and inactive regions of the genome to mingle and misfire. This structural breakdown, mapped for the first time using single-cell technology and artificial intelligence, disrupts the regulatory switches that control synaptic function and cellular metabolism.[1][5]

The discovery, published in the journal Science, adds a fundamental new layer to the understanding of the neurodegenerative disorder. While traditional research has focused on the accumulation of amyloid-beta plaques and tau tangles, a multi-institutional team led by Carnegie Mellon University and the University of Pittsburgh demonstrated that the disease also degrades the spatial organization of the genome itself.[1][6]

DNA does not sit inside a cell nucleus as a simple, straight strand. It is intricately folded and coiled so that specific regulatory elements, such as enhancers, are brought into physical contact with the genes they control. In a healthy brain cell, the genome is broadly divided into 2 primary spatial domains: active A compartments and inactive B compartments, which maintain clear spatial boundaries.[4][5]

In Alzheimer's-affected cells, those boundaries collapse. Researchers observed a phenomenon they termed 'compartment mingling,' where the distinct separation between active and inactive genomic regions is lost. This spatial degradation weakens the vital contacts between genes and their regulatory enhancers, while simultaneously increasing abnormal long-range genomic contacts.[4][5]

Although clinicians have recognized Alzheimer's disease since the early 1900s, and the first genetic link was identified in 1987, the exact mechanisms driving cellular decline have remained elusive. To uncover the structural changes, the research team utilized a single-cell co-assay called GAGE-seq, which they unveiled in 2024. The technique simultaneously measures 3D genome structure and gene expression within the exact same cell.[3][4]

The researchers applied this method to postmortem prefrontal cortex tissue donated by individuals involved in a dementia study at the Rush Alzheimer's Disease Center. The resulting data was fed into Hicformer, a deep learning transformer model developed by the computational team. Trained on over 7,500 genes across 13 distinct cell types under both Alzheimer's and non-Alzheimer's conditions, the AI framework predicted how changes in chromosome structure alter specific cellular functions.[4][5]

The structural decay directly correlated with cellular dysfunction. In neurons, the increased chromatin mingling was associated with a reduction in the activity of genes responsible for synaptic function and communication. Conversely, in microglia—the brain's resident immune cells—the structural changes upregulated genes linked to metabolic stress, inflammation, and cellular senescence.[4][5]

"Alzheimer's disease cannot be understood one layer at a time," said Jian Ma, the Ray and Stephanie Lane Professor of Computational Biology at Carnegie Mellon, who led the study. "The genome's 3D structure is a fundamental regulatory layer that helps to connect DNA sequence to gene activity."[1][6]

The findings align with parallel research supported by the National Institutes of Health's 4D Nucleome program, which found a similar overall loss of 3D genome organization associated with natural aging. A separate team led by researchers at the University of California, Irvine, and the University of California, San Diego, looked at cells from the brain's hippocampus and found that age-related structural decay coincided with changes in gene activity and chemical marks on the DNA.[2]

Because aging is the primary risk factor for Alzheimer's, the overlapping structural decay suggests that the physical packing of DNA within the nucleus is a critical vulnerability over time. The identification of this regulatory layer shifts the focus toward the genome's control systems. Future studies will investigate whether these newly mapped regulatory regions could serve as early diagnostic markers or targets for precision gene therapies, potentially allowing clinicians to reprogram the genetic switches before the onset of neurodegeneration.[1][2]